Datasets:

Venkat-Ram-Rao
/

docvqa-tables-lists

Modalities:

Image

Text

Formats:

Size:

Libraries:

Dataset card Viewer Files Files and versions Community

Dataset Viewer

Auto-converted to Parquet

Full Screen Viewer

Full Screen

Split (1)

train · 12.5k rows

questionId int32 388 65.4k	question stringlengths 11 171	question_types listlengths 1 4	docId int32 223 14.9k	ucsf_document_id stringlengths 8 8	ucsf_document_page_no stringclasses 183 values	answers listlengths 1 5
388	How many points are there in modifications to readout instrumentation	[ "table/list" ]	297	sxxj0037	2	[ "5.", "5" ]
416	what is the index for Retention of Franchise	[ "table/list" ]	355	rzbj0037	9	[ "100", "(100)" ]
437	How many distinct mechanisms appear to play a role in the breakup of a smoke column into a multi-dimensional flowfield?	[ "table/list", "free_text" ]	303	nmcj0037	1	[ "Two", "At least two" ]
438	One variable that has implicitly not been controlled?	[ "table/list", "free_text" ]	303	nmcj0037	1	[ "influence of the test chamber (glass mouth) geometry.", "The influence of the test chamber (glass mouth) geometry" ]
456	What is the S.D. mentioned in the DOSE-ug 0.0000 in the third table?	[ "table/list" ]	313	hgbl0037	9	[ "10.6" ]
479	What is RIP-6 value for KOOL KS?	[ "table/list" ]	317	rncj0037	4	[ "6I/6" ]
481	What is the cigarette code of RIP-6(W/O Filter) 21/4SE	[ "table/list" ]	317	rncj0037	4	[ "P4049-99(5C)" ]
487	According to the listed requirements , what must be the age group of female smokers?	[ "table/list" ]	319	fxxj0037	2	[ "between the ages of 18 and 55" ]
488	According to the requirements what is the minimum required consumption of a regular brand?	[ "table/list" ]	319	fxxj0037	2	[ "1/2 pack" ]
493	What is the LBS AT TARGET of TOTAL STRIPS?	[ "table/list" ]	321	lycj0037	5	[ "10,000.0 @ 15.0 %" ]
494	What is the SOLID LBS of T2F GRADE?	[ "table/list" ]	321	lycj0037	5	[ "510.0", "510" ]
507	Which inks give significantly lower filter flare-up rates?	[ "table/list", "free_text" ]	323	xhxj0037	2	[ "low silicate inks" ]
517	What is the share of the 21-25 segment mentioned?	[ "table/list" ]	326	rzbj0037	4	[ "0%" ]
518	What is the index value for Retention of Franchise ?	[ "table/list" ]	326	rzbj0037	4	[ "(100)", "100" ]
525	What is the Ecusta of Cig. Code 498062 mentioned in RIP-6?	[ "table/list" ]	341	rncj0037	3	[ "6I/6" ]
529	Which is more superior out of Ultra KS Prototype or Salem Ultra 100 among rep mentol ultra smokers?	[ "table/list" ]	328	hyhk0037	10	[ "Ultra KS Prototype" ]
530	KOOL "C" With Conventional Filter Will Be Adopted Based On The Acceptability Of The?	[ "table/list" ]	328	hyhk0037	10	[ "The Kool LTS KS CPT results", "KOOL LTS KS CPT Results" ]
539	What is the date mentioned in the document ?	[ "table/list" ]	331	sxxj0037	1	[ "June 19, 1990" ]
542	What is the third point mentioned in Project Basis Technologies?	[ "table/list" ]	332	hyhk0037	3	[ "Increased Humectants" ]
548	What is the STRAIN TA100,REV/CIG of G7-25 with 1.0% turkish extract?	[ "table/list" ]	335	hgbl0037	2	[ "12621" ]
549	What is the sample of the STRAIN TA100, REV/MG TAR 1094?	[ "table/list" ]	335	hgbl0037	2	[ "Low extract G7 with 0.5% turkish extract" ]
562	What is the Retention of Franchise?	[ "table/list" ]	337	rzbj0037	10	[ "79.2%", "79.2% (98)" ]
563	What is the Index of Single Brand Users in the Franchise?	[ "table/list" ]	337	rzbj0037	10	[ "119", "(119)" ]
564	What is the share of the 21-25 segment mentioned?	[ "table/list" ]	337	rzbj0037	10	[ "0.5%", "0.5% (50)" ]
577	what is the CGR for the age group 21-25?	[ "table/list" ]	346	rzbj0037	1	[ "-0.68%" ]
578	which age group is having the highest estimated growth rate or CGR?	[ "table/list" ]	346	rzbj0037	1	[ "51+" ]
579	which age group is having the lowest estimated growth rate or CGR?	[ "table/list" ]	346	rzbj0037	1	[ "26-35" ]
586	which brands did camel exotic blends compliment?	[ "table/list", "free_text" ]	351	tynx0037	3	[ "the brand's Turkish and Domestic blend with rare tobaccos and flavorful spices", "Turkish and domestic blend ." ]
590	How are speciality blends packed?	[ "table/list", "free_text" ]	351	tynx0037	3	[ "In stylish tins with graphics", "stylish tins with graphics" ]
621	What is the DEXTROSE (GLUCOSE) level?	[ "table/list" ]	363	ykpj0226	10	[ "42", "42%" ]
658	what is the gross profit in the year 2009?	[ "table/list" ]	376	mxpj0226	6	[ "19,902", "19,902 millions" ]
659	what is the income before income tax for the year 2007?	[ "table/list" ]	376	mxpj0226	6	[ "7,919", "7919", "7,919 millions" ]
660	what is the basic net income per share for 2009 vs 2008	[ "table/list" ]	376	mxpj0226	6	[ "18%" ]
661	what is the consolidated net income in the year 2008	[ "table/list" ]	376	mxpj0226	6	[ "5,874", "5,784 millions" ]
662	what is the operating margin in the year 2009	[ "table/list" ]	376	mxpj0226	6	[ "26.6%" ]
698	which country is benefited from the successful integration of jugos de valle?	[ "table/list", "free_text" ]	387	lxpj0226	8	[ "Latin America" ]
716	What is the average calories decreased over the past decade in the United States?	[ "table/list", "free_text" ]	391	jxpj0226	7	[ "11%" ]
718	In which year diet coke was introduced in United States?	[ "table/list", "free_text" ]	391	jxpj0226	7	[ "1982" ]
775	who conducted pivotal studies	[ "table/list", "free_text" ]	634	yljf0226	2	[ "Takeda" ]
776	What findings are not duplicated in mouse, monkey, or dog?	[ "table/list", "free_text" ]	634	yljf0226	2	[ "Rat", "Rat Findings" ]
778	quantity of the product code 15102	[ "table/list" ]	638	szjf0226	1	[ "1" ]
860	what is the 2nd point inthe letter ?	[ "table/list", "free_text" ]	424	rfpj0226	1	[ "Reaffirm our decades-old strict policy and guidelines regarding the marketing and advertising of our brands to children." ]
915	What is the second reference mentioned?	[ "table/list" ]	438	pkpj0226	6	[ "PepsiCo, Inc., The Physical or Technical Effect of Caffeine in Cola Beverages, Purchase, N.Y., July 20, 1981" ]
917	Which university does the sixth reference mention?	[ "table/list" ]	438	pkpj0226	6	[ "University of Florida" ]
918	Which year is mentioned in the first reference?	[ "table/list" ]	438	pkpj0226	6	[ "1983" ]
972	Who is the 23rd Addressee mentioned in the list?	[ "table/list", "layout" ]	470	srjf0226	17	[ "Senior Vice President, Accounting Center" ]
975	What are the timings for Continental Breakfast?	[ "table/list" ]	471	xsjf0226	3	[ "8:00-9:00" ]
983	what is the first point under the title-executive summary, cont.	[ "table/list" ]	480	xsjf0226	6	[ "Proposed experiments", "proposed experiments" ]
1,066	By whom is this document written?	[ "table/list", "layout" ]	511	ksjf0226	4	[ "Stacey Dixon Calahan" ]
1,107	What is the fifth point?	[ "table/list", "layout" ]	510	frjf0226	3	[ "WAC and AWP generally;", "WAC AND AWP generally;" ]
1,108	Education grants regarding which products?	[ "table/list", "free_text" ]	510	frjf0226	3	[ "TPNA", "TPNA products" ]
1,111	Which reimbursement for TPNA pharmaceutical products is generally given?	[ "table/list", "free_text" ]	510	frjf0226	3	[ "Medicare and Medicaid" ]
1,115	What is the full form of FAR?	[ "table/list", "free_text", "layout" ]	512	zfkf0226	5	[ "Federal Acquisitions Regulation" ]
1,177	What is the due date to evaluate data from actos 507?	[ "table/list", "layout" ]	535	qtjf0226	4	[ "August 5" ]
1,178	who is the lead responsibility for developing additional monitoring plan for actos 508	[ "table/list", "layout" ]	535	qtjf0226	4	[ "Amy Hagaman", "Amy hagaman" ]
1,179	what is the due date for "draft justification for actos 508" ?	[ "table/list", "layout" ]	535	qtjf0226	4	[ "August 12", "august 12" ]
1,181	Who is the lead responsible person for draft justification for actos 508?	[ "table/list", "layout" ]	535	qtjf0226	4	[ "Amy Hagaman/Alfonso Perez" ]
1,225	What is the last point in the table?	[ "table/list", "layout" ]	548	qtjf0226	8	[ "Evaluate Impact on Tak-559", "EVALUATE IMPACT ON TAK-559" ]
1,227	What is the Draft's Due Date?	[ "table/list", "layout" ]	548	qtjf0226	8	[ "August 5" ]
1,228	Which benefit start after 1 year of service?	[ "table/list", "layout" ]	501	ttjf0226	5	[ "Extended Disability", "extended disability" ]
1,230	Which drug's toxicity study results will be discussed ?	[ "table/list", "free_text", "layout" ]	526	pljf0226	6	[ "pioglitazone" ]
1,241	What is the due date to conduct review meeting for FDA package?	[ "table/list" ]	551	qtjf0226	7	[ "August 22" ]
1,243	Who is the lead responsible person for the compilation of FDA package?	[ "table/list" ]	551	qtjf0226	7	[ "Larry Hancock" ]
1,247	What is the task assigned to David Baron?	[ "table/list" ]	551	qtjf0226	7	[ "Send nonclinical rationale/justification section to medical writing for compilation", "Send nonclinical rationale/justification section to medical writing for compilation." ]
1,248	Who is responsible for sending package to TCI/EU for review?	[ "table/list" ]	551	qtjf0226	7	[ "Mary Ramstack" ]
1,249	What is the due date for sending FDA Document to Regulatory Affairs?	[ "table/list" ]	551	qtjf0226	7	[ "August 26" ]
1,255	Mention the first name listed in the "apologies"?	[ "table/list" ]	553	ltjf0226	1	[ "Professor Ele Ferrannini" ]
1,271	mention the second point listed under the article 7(document storage period)?	[ "table/list", "layout" ]	556	jpjf0226	3	[ "To be stored for ten years", "to be stored for ten years" ]
1,295	which are prescibed eariler in the treatment of type 2 diabetes under the title of "critical success factors"?	[ "table/list", "free_text" ]	565	ynjf0226	17	[ "TZD'S", "TZD's" ]
1,301	What is the Plan TZD Share for the year 2003?	[ "table/list" ]	586	ynjf0226	3	[ "19.7%" ]
1,303	Which year has 13.3% Oral share (TZD)?	[ "table/list" ]	586	ynjf0226	3	[ "2000" ]
1,304	which has a superior lipid profile(v. avandia and others) under the title of "strength/opportunities?	[ "table/list", "free_text" ]	565	ynjf0226	17	[ "ACTOS" ]
1,311	When was expert advisory meeting ?	[ "table/list", "free_text" ]	571	jfkf0226	4	[ "4 OCTOBER 2006", "4 october 2006" ]
1,313	What is the full form of PPSR?	[ "table/list", "others" ]	599	jfkf0226	3	[ "PROPOSED PEDIATRIC STUDY REQUEST", "Proposed Pediatric Study Request" ]
1,316	What study is described in the table given?	[ "table/list", "layout" ]	605	hfkf0226	7	[ "PLACEBO- CONTROLLED DOSE RANGING STUDY", "Glycemic Parameters in a 26-Week Placebo-Controlled Dose-Ranging Study." ]
1,328	What is the goal of TPNA?	[ "table/list" ]	620	yljf0226	1	[ "to supply justification to support maintaining current labeling." ]
1,329	what is the first point given in table for bladder cancer alongside of clinical findings ?	[ "table/list" ]	575	trjf0226	4	[ "OBSERVED DURING PRECLINICAL STUDIES IN RATS", "observed during preclinical studies in rats" ]
1,333	what is the percentage of TZD share in the year 2000 ?	[ "table/list" ]	584	ynjf0226	4	[ "40.3%" ]
1,335	what is Actos TRx (000s) in the year 2003 ?	[ "table/list" ]	584	ynjf0226	4	[ "9,497" ]
1,337	how much percent of drug quantity present in rezulin under the title of 'clinical findings'?	[ "table/list" ]	575	trjf0226	4	[ "1.7%", "1.7" ]
1,339	what is the percentage of plan TZD share in the year 2004 ?	[ "table/list" ]	584	ynjf0226	4	[ "42.9%" ]
1,340	how much percent of placebo present in avandia alongside of the clinical findings?	[ "table/list" ]	575	trjf0226	4	[ "0.20%", "0.20" ]
1,342	what is the TZD's TRx (000s) in the year 2005 ?	[ "table/list" ]	584	ynjf0226	4	[ "22,902" ]
1,343	what is the total number of all claims under the title of "summary of litigation risk in the ous territories"?	[ "table/list" ]	575	trjf0226	4	[ "10" ]
1,344	what is the first TZD used for type 2 patients ?	[ "table/list", "free_text" ]	585	ynjf0226	13	[ "ACTOS", "Actos" ]
1,345	For which type of diabetes the TZD's prescribed earlier in treatment?	[ "table/list", "free_text" ]	585	ynjf0226	13	[ "Type 2 diabetes" ]
1,350	what is included in the summary document ?	[ "others", "table/list", "free_text" ]	588	jfkf0226	2	[ "includes benefit-risk assessment", "benefit risk assessment", "(includes benefit-risk assessment)" ]
1,352	what is the executive summary of bladder cancer cases ?	[ "table/list" ]	588	jfkf0226	2	[ "CONFIRM" ]
1,354	what is the name of the request document ?	[ "table/list", "layout" ]	588	jfkf0226	2	[ "PARTIAL CLINICAL HOLD REMOVAL REQUEST DOCUMENT", "Partial clinical hold removal request document", "PARTIAL CLINICAL HOLD REMOVAL" ]
1,356	who appointed as the responsible person on this issue ?	[ "table/list", "free_text" ]	594	ymjf0226	1	[ "MR. SAITO", "Mr. Saito" ]
1,358	basically by whom the current action plan was approved ?	[ "table/list", "free_text" ]	594	ymjf0226	1	[ "CEO" ]
1,360	in which month and date it was reported to CEO ?	[ "table/list", "free_text" ]	594	ymjf0226	1	[ "AUGUST 6", "August 6" ]
1,363	what has to be reported to CEO on August 20 (japan time) ?	[ "table/list", "free_text" ]	594	ymjf0226	1	[ "AN OUTLINE OF THE FDA RESPONSE", "an outline of the FDA response" ]
1,369	who is the chief leader ?	[ "table/list" ]	598	ymjf0226	2	[ "MR. K SAITO", "Mr.K Saito" ]
1,371	who is the responsible person for TPNA ?	[ "table/list" ]	598	ymjf0226	2	[ "Dr. C Thom" ]
1,374	who is the responsible person of TCI ?	[ "table/list" ]	598	ymjf0226	2	[ "MR. K SAITO" ]
1,377	who is the first contact person of EuR&D ?	[ "table/list" ]	598	ymjf0226	2	[ "DR. P COLLETT", "Dr. P Collett" ]
1,380	who is the responsible person for EuR&D ?	[ "table/list" ]	598	ymjf0226	2	[ "DR. D ECKLAND", "Dr. D Eckland" ]
1,382	who is the first contact person of TPNA ?	[ "table/list" ]	598	ymjf0226	2	[ "MS. M RAMSTACK, MS. J HASKINS", "Ms. M Ramstack ,Ms. J Haskins" ]
1,385	who is the first contact person of TCI ?	[ "table/list" ]	598	ymjf0226	2	[ "MR. M MIYAZAKI", "Mr. M Miyazaki" ]